| Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
| Biotech Growth Trust (the) Plc |
LSE:BIOG |
London |
Ordinary Share |
GB0000385517 |
ORD 25P |
| |
Price Change |
% Change |
Share Price |
Shares Traded |
Last Trade |
| |
16.00 |
2.01% |
814.00 |
71,582 |
16:29:59 |
| Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
|
802.00
|
818.00
|
828.00 |
800.00 |
816.00 |
| Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
|
Equity Investment Instruments
|
1.25
|
0.70
|
1.00
|
814.0
|
343
|
| Last Trade Time |
Trade Type |
Trade Size |
Trade Price |
Currency |
| 16:35:17 |
UT |
4,432 |
814.00 |
GBX |
| Trade Time |
Trade Price |
Trade Size |
Trade Value |
Trade Type |
| 15:35:17 | 814.00 | 4,432 | 36,076.48 | UT |
| 15:25:23 | 815.86 | 600 | 4,895.16 | O |
| 15:16:55 | 814.00 | 300 | 2,442.00 | AT |
| 15:16:52 | 813.88 | 614 | 4,997.22 | O |
| 15:16:30 | 813.85 | 98 | 797.57 | O |
| Date | Subject |
|---|
31/3/2020
09:20 | Biotech Growth Daily Update: Biotech Growth Trust (the) Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker BIOG. The last closing price for Biotech Growth was 798p.
Biotech Growth Trust (the) Plc has a 4 week average price of 680p and a 12 week average price of 680p.
The 1 year high share price is 1,015p while the 1 year low share price is currently 662p.
There are currently 42,177,824 shares in issue and the average daily traded volume is 108,732 shares. The market capitalisation of Biotech Growth Trust (the) Plc is £343,327,487.36.
|
04/4/2018
00:56 | andyj: Share price nearly 10% below NAV now, should see some buy backs.
|
22/11/2014
20:58 | philo124: Just read their Report and Accounts; not sure I should have sold even at these levels- looks like the story and share price has further to go in 2015.
|
10/4/2014
13:26 | urgentclick: Looks good to me: downside recently around 409p (I picked up 1000 at that price point) and upside 550p not long ago. And the NAV comfortably exceeding the share price.
|
14/1/2013
00:50 | yiyack3: In my experience many AIM companies are pretty well worthless, run by a CEO and a crony or two who like the good life, first class on expenses, get rich as quick as poss and don't worry when the company runs out of cash, goes bust and all the shareholders lose their investments. If an AIM company gets to be popular on the ADVFN and other bulletin boards, do what you can to hitch a ride on rising share price, then take profits and get out. Don't ever believe the story behind an AIM market share
|
29/7/2012
20:24 | northernlass: THE QUARTER'S BEST PERFORMER
Looking at individual investment portfolios, the Biotech Growth trust was the quarter's best performer in terms of both net asset value (NAV) and share price. Over the three months, its NAV rose 19.1% while share price was up 11.4% on a total return basis.
Source:
http://www.fundweb.co.uk/investment-trusts/news/trusts-ahead-of-open-ended-peers-despite-q2-underperformance/1053944.article
|
21/7/2010
18:33 | chingman: Latest from Edison -
The Biotech Growth Trust Plc (BIOG) has put in a respectable performance during the past 12 months, outperforming its benchmark, the NASDAQ Biotechnology Index (sterling adjusted), by 2.8% in terms of NAV total return and 3.9% in terms of share price total return. The manager believes that concerns over US healthcare reform were overdone and, while this cloud of uncertainty has lifted, concerns regarding the outlook in Europe have delayed the reversion. Looking forward, the manager considers that; biotech will be a net beneficiary of healthcare reform; the regulatory environment will continue to improve; M
|
26/1/2010
19:28 | damanko: Ian - two is a crowd ...............
I didn't bother participating in the recent fund raising, as the amount payable (ie the stated NAV) was some way north of the share price. In fact, I meant to write to the board, and ask who on earth would bother (amongst longer term holders) - when this was the case. Whatever, the institutions were keen, and the price has carried on its mild upward trend.
Worth tucking away. Mind you, having bought about nine years ago, I'm now only 25% or so down on what I paid. Ho hum....
|
Biotech Growth share price data is direct from the London Stock Exchange
PLUS1
